Researchers published a Nature Communications report describing a bioengineered viral platform that edits RNA inside macrophages in vivo to modulate inflammatory responses in sepsis models. The chemogenetic system enables cell‑type–selective RNA editing, allowing therapeutic modulation of immune effectors without systemic gene editing of other tissues. The paper demonstrates proof‑of‑concept in preclinical models with improved survival and reduced inflammatory markers. The approach could open a translational path for severe infection and inflammatory syndromes, but investigators highlighted the need for additional safety and biodistribution studies before human trials.